#heateor_sss_mastodon_popup_bg,#heateor_sss_popup_bg{--wpr-bg-9b170f74-f044-495f-b4b6-265a96f3b718: url('https://www.delveinsight.com/blog/blog/wp-content/plugins/sassy-social-share/images/transparent_bg.png');}.rll-youtube-player .play{--wpr-bg-580bbb8c-540b-404f-a959-4fda6a4341dc: url('https://www.delveinsight.com/blog/wp-content/plugins/wp-rocket/assets/img/youtube.png');}

0

Home Blog Tag Ryplazim

Ryplazim

Nov 29, 2018

Prometic bags $50M; Vedanta receives $12M; Humira biosimilar deal

Prometic bags USD 50 Million stock sale option to ease a cash crunch Prometic Life Sciences got into an agreement for selling USD 50 million in stock. This gives Prometic a way to escape its current financial pressures. Canada-based Prometic was asked by the FDA to make and validate process changes for Ryplazim, a c...

Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies

Snippets - A Small piece of News or Article

Jul 04, 2025

A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray

Articles

Jun 10, 2025

ADCs in Lung Cancer Treatment: ENHERTU’s Rise, HER3 & TROP-2 Challenges, and What’s Next in the Pipeline

Articles

May 09, 2025

LEQEMBI: A New Hope for Alzheimer’s Disease Patients

Articles